Key result
Targeting the Angiopoietin/Tie2 pathway in tumor vessels is discussed as a double-edged sword in this editorial.
Answers are grounded in this paper and cite their sources.
Highlights dual vascular effects of Ang/Tie2 targeting in tumors; leaves open net benefit and optimal strategies for trials.
Article Tools UNDERSTANDING THE PATHWAY Article Tools OPTIONS & TOOLS Export Citation Track Citation Add To Favorites Rights & Permissions COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.2011.38.7621 Journal of Clinical Oncology - published online before print December 19, 2011 PMID: 22184396 Targeting the Angiopoietin/Tie2 Pathway: Cutting Tumor Vessels With a Double-Edged Sword? Tina CasconexTina CasconeSearch for articles by this author , John V. HeymachxJohn V. HeymachSearch for articles by this author Show More The University of Texas MD Anderson Cancer Center, Houston, TX https://doi.org/10.1200/JCO.2011.38.7621 First Page Full Text PDF Figures and Tables Supplements © 2011 by American Society of Clinical Oncology
No takes yet. Share an insight, caveat, or question.
Cascone et al. (2011) reported an editorial. Targeting the Angiopoietin/Tie2 Pathway was evaluated. Targeting the Angiopoietin/Tie2 pathway in tumor vessels is discussed as a double-edged sword in this editorial.
Synapse has enriched 10 related papers. Consider them for comparative context: